Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.

Breast cancer research and treatment - 1 Jun 2016

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R

Abstract excerpt

Oncotype-DX assay has never been validated for BRCA mutation carriers. This study compares the recurrence score (RS) distribution in BRCA-positive breast cancer patients with that of a general population (GP) of patients and reports their outcomes. Eligible patients were BRCA carriers who performed the Oncotype-DX assay. Two sets of databases were cross-linked: BRCA carriers at Rabin Medical Center and Sheba...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Genetic

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to Receptors, Estrogen

Share to Risk Assessment

Source

Identifiers

PMID: 27225387
DOI: 10.1007/s10549-016-3836-6

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.PMID 27225387Read ↗

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.Semantic proximity Read ↗

Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.Semantic proximity Read ↗

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read ↗

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Comparison of time-varying recurrence patterns in breast cancer patients with different molecular subtypes treated from 2008 to 2012 and from 2013 to 2016: a single-center retrospective studySemantic proximity Read ↗

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read ↗

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read ↗

Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutationsSemantic proximity Read ↗

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read ↗

Evaluation of an AI-Based Digital Pathology Tool for Breast Cancer Recurrence RiskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.